Albany Molecular Research, Inc. (AMRI), a global provider of advanced contract research, development and manufacturing solutions, has appointed Scott Waldman as senior vice president, corporate development. Waldman will drive key growth initiatives globally, including mergers and acquisitions (M&A), and serve as a member of the company’s executive committee.
 
“We are delighted to welcome Scott to the AMRI organization to lead this critical function,” said John Ratliff, chief executive officer, AMRI. “He brings extensive industry and transaction expertise to our organization. Scott has built an impressive track record of delivering growth throughout his career. He knows the space and understands the inherent complexities of our business. I’m confident that Scott will be a key contributor to AMRI’s continued growth journey.”
 
Waldman brings more than 25 years of experience to the role, in corporate development and as a general counsel and corporate lawyer, with more than 15 years focused on the pharmaceutical and pharmaceutical services industries. Most recently, he served as an advisor to private equity firms and select pharma industry clients. Previously, Waldman worked in a number of executive roles at Lonza Group, including chief strategy officer, where he led Lonza’s M&A activities.